Drug Profile
Research programme : staphylococcal infections vaccine - Serenta Biotechnology
Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Northern Arizona University; University of Maryland, Baltimore
- Developer Serenta Biotechnology
- Class Bacterial vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Staphylococcal infections
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Staphylococcal-infections(Prevention) in USA (Parenteral)
- 01 Jun 2017 The University of Maryland and Northern Arizona University co-own the intellectual property rights for multivalent staphylococcal aureus infections vaccine
- 01 Jun 2017 Preclinical development for Staphylococcal infections (Prevention) in USA (Parenteral) before June 2017